AstraZeneca COVID-19 vaccine 79% effective in preventing symptomatic illness, company says
March 22 2021, 08:00
AstraZeneca said in a statement early Monday the Phase III trial of its COVID-19 vaccine –which was conducted in the U.S.—showed a 79% effectiveness in preventing symptomatic infections and a 100% efficacy “at preventing severe disease and hospitalization.”
AstraZeneca said in a statement early Monday the Phase III trial of its COVID-19 vaccine –which was conducted in the U.S.—showed a 79% effectiveness in preventing symptomatic infections and a 100% efficacy “at preventing severe disease and hospitalization.”
Source:
FOX News